Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: The EBMT transplant consensus

Leukemia

Volumn 21, Issue 1, 2007, Pages 12-17

  Dreger, P ^a   Corradini, P ^b   Kimby, E ^c   Michallet, M ^d   Milligan, D ^e   Schetelig, J ^f   Wiktor Jedrzejczak, W ^g   Niederwieser, D ^h   Hallek, M ⁱ   Montserrat, E ^j  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF MILAN   (Italy)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g MEDICAL UNIVERSITY OF WARSAW   (Poland)

^h UNIVERSITY OF LEIPZIG   (Germany)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

^j UNIVERSITY OF BARCELONA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; PURINE DERIVATIVE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LEUKEMIA; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CLINICAL TRIAL; DONOR; DRUG EFFICACY; EDITORIAL; EVIDENCE BASED MEDICINE; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFORMATION PROCESSING; INTERNATIONAL COOPERATION; MEDICAL EXPERT; MEDLINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; TREATMENT RESPONSE; WHOLE BODY RADIATION;

EID: 33845543049     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404441     Document Type: Editorial

References (43)

1. Pavletic ZS, Arrowsmith ER, Bierman PJ, Goodman SA, Vose JM, Tarantolo SR et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant 2000; 25: 717-722.
2. Khouri IF, Keating MJ, Saliba RM, Champlin RE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 2002; 4: 217-221.
3. Michallet M, Archimbaud E, Rowlings PA, Bandini G, Horowitz MM, Bortin MM et al. HLA-identical sibling bone marrow transplants for chronic lymphocytic leukemia. Ann Intern Med 1996; 124: 311-315.
4. Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: The Cooperative German Transplant Study Group. J Clin Oncol 2003; 21: 2747-2753.
5. Sorror ML, Maris MB, Sandmaier BM, Storer B, Jain-Stuart M, Al-Ali H et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3819-3829.
6. Caballero D, Garcia-Marco JA, Martino R, Mateos V, Ribera JM, Sarra J et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities. Clin Cancer Res 2005; 11: 7757-7763.
7. Mattsson J, Uzunel M, Remberger M, Ljungman P, Kimby E, Ringden O et al. Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. Leukemia 2000; 14: 247-254.
8. Esteve J, Villamor N, Colomer D, Montserrat E. Different clinical value of minimal residual disease after autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Blood 2002; 99: 1873-1874.
9. Dreger P, Brand R, Milligan D, Corradini P, Finke J, Lambertenghi-Deliliers G et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: A population-matched analysis. Leukemia 2005; 19: 1029-1033.
10. Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC et al. Autologous and allogeneic stem cell transplantation for poor risk chronic lymphocytic leukemia. Blood 2005; 106: 4389-4396.
11. Rondon G, Giralt S, Huh Y, Khouri I, Andersson B, Andreeff M et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996; 18: 669-672.
12. Dreger P, Ritgen M, Böttcher S, Schmitz N, Kneba M. The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: Is achievement of molecular remission worthwile? Leukemia 2005; 19: 1135-1138.
13. Moreno C, Villamor N, Esteve J, Colomer D, Bosch F, Campo E et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006; 107: 4563-4569.
14. Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2004, 163-183.
15. Gribben JG. Salvage therapy for CLL and the role of stem cell transplantation. Hematology (Am Soc Hematol Educ Program) 2005, 292-298.
16. Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Gine E, Bosch F. How I treat refractory CLL. Blood 2006; 107: 1276-1283.
17. Ritgen M, Stilgenbauer S, von Neuhoff N, Humpe A, Brüggemann M, Pott C et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy chain gene status: Implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104: 2600-2602.
18. Keating MJ, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43: 1755-1762.
19. Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: Implications for clinical trials in this patient population. Cancer 2002; 94: 2033-2039.
20. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070-4078.
21. O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 1414-1420.
22. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 2002; 99: 3554-3561.
23. Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278-3281.
24. Mauro FR, Foa R, Giannarelli D, Cordone I, Crescenzi S, Pescarmona E et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: A single institution study of 204 cases. Blood 1999; 94: 448-454.
25. Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165-1171.
26. Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 976-984.
27. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079-4088.
28. Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580-1587.
29. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
30. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 2006; 24: 437-443.
31. Kröber A, Bloehdorn J, Hafner S, Buhler A, Seiler T, Kienle D et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and. J Clin Oncol 2006; 24: 969-975.
32. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
33. H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
34. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-1775.
35. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944-4951.
36. Hamblin M, Orchard JA, Gardiner A, Oscier DG, Davis Z, Stevenson FK. Immunoglobulin V genes and CD38 expression in CLL. Blood 2000; 95: 2455-2457.
37. Durig J, Nuckel H, Huttmann A, Kruse E, Holter T, Halfmeyer K et al. Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. Blood 2003; 101: 2748-2755.
38. Deaglio S, Vaisitti T, Aydin S, Ferrero E, Malavasi F. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006; 108: 1135-1144.
39. Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006; 107: 1276-1283.
40. Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR et al. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: Results from the center for international blood and marrow transplant research. J Clin Oncol 2005; 23: 5788-5794.
41. Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 2006; 24: 2343-2351.
42. Dearden CE, Matutes E, Cazin B, Tjonnfjord GE, Parreira A, Nomdedeu B et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001; 98: 1721-1726.
43. Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedeu J et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3433-3438.